Publication | Closed Access
Semisynthetic Insulin Analogues Modified in Positions B24, B25 and B29
14
Citations
13
References
1994
Year
Medicinal ChemistryBiochemistryNew Semisynthetic AnaloguesPositions B24Natural SciencesDiabetesMedicinePeptide LibrarySynthetic OctapeptidesInsulin ManagementPeptide SynthesisProtein EngineeringHuman InsulinInsulin DeliveryChemical BiologyPharmacologyInsulin SignalingDrug Discovery
New semisynthetic analogues of human insulin, modified in the C-terminal region of the B-chain, were prepared to refine our understanding of the importance of particular amino acid residues in the expression of hormone biological properties. The following insulin analogues were synthesized by trypsin-catalyzed peptide-bond formation between the C-terminal arginineB22 of des-octapeptide(B23-B30)-insulin and synthetic octapeptides with the epsilon-amino group of lysineB29 protected by a phenylacetyl group: [L-Lys(Pac)B29]insulin, [D-PheB24,B25,L-Lys(Pac)B29]insulin and [D-Phe(p-Et)B24, L-Lys(Pac)B29]insulin. Enzymatic deprotection using immobilized penicillin amidohydrolase yielded: human insulin, [D-PheB24,B25]insulin and [DPhe(p-Et)B24]-insulin. Biological in vitro potencies (specific binding to cultured human lymphocytes IM-9 and lipogenic potency in isolated rat adipocytes) of the semisynthetic analogues were estimated, ranging from 0.2 to 100% relative to porcine insulin.
| Year | Citations | |
|---|---|---|
Page 1
Page 1